Mylan Eylea Biosimilar Gets Green Signal For Trials In India
Executive Summary
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.